The neglected intrinsic resistome of bacterial pathogens by Fajardo, A. et al.
The Neglected Intrinsic Resistome of Bacterial Pathogens
Alicia Fajardo1, Nadia Martı´nez-Martı´n1, Marı´a Mercadillo2, Juan C. Gala´n2,3,4, Bart Ghysels5, Sandra
Matthijs5, Pierre Cornelis5, Lutz Wiehlmann6, Burkhard Tu¨mmler6, Fernando Baquero2,3,4, Jose´ L.
Martı´nez1,2,3*
1Departamento de Biotecnologı´a Microbiana, Centro Nacional de Biotecnologı´a, Consejo Superior de Investigaciones Cientı´ficas (CSIC), Cantoblanco, Madrid, Spain,
2Unidad Asociada al Centro Nacional de Biotecnologı´a, Consejo Superior de Investigaciones Cientı´ficas (CSIC) ‘‘Resistencia a los antibio´ticos y virulencia bacteriana’’,
Hospital Ramo´n y Cajal, Madrid, Spain, 3CIBER Epidemiologı´a y Salud Pu´blica (CIBERESP), Hospital Ramo´n y Cajal, Madrid, Spain, 4Departamento de Microbiologı´a,
Hospital Ramo´n y Cajal, Madrid, Spain, 5 Laboratory of Microbial Interactions, Department of Molecular and Cellular Interactions, Flanders Interuniversity Institute for
Biotechnology, Vrije Universiteit Brussel, Brussels, Belgium, 6 Klinische Forschergruppe, Medizinische Hochschule Hannover, Hannover, Germany
Abstract
Bacteria with intrinsic resistance to antibiotics are a worrisome health problem. It is widely believed that intrinsic antibiotic
resistance of bacterial pathogens is mainly the consequence of cellular impermeability and activity of efflux pumps.
However, the analysis of transposon-tagged Pseudomonas aeruginosa mutants presented in this article shows that this
phenotype emerges from the action of numerous proteins from all functional categories. Mutations in some genes make P.
aeruginosa more susceptible to antibiotics and thereby represent new targets. Mutations in other genes make P. aeruginosa
more resistant and therefore define novel mechanisms for mutation-driven acquisition of antibiotic resistance, opening a
new research field based in the prediction of resistance before it emerges in clinical environments. Antibiotics are not just
weapons against bacterial competitors, but also natural signalling molecules. Our results demonstrate that antibiotic
resistance genes are not merely protective shields and offer a more comprehensive view of the role of antibiotic resistance
genes in the clinic and in nature.
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Introduction
The large increase in human life expectancy during the last
century is attributable, among other factors, to the effectiveness of
antibiotics in curing formerly devastating infectious diseases and,
particularly in enabling the application of effective but aggressive
medical and surgical techniques to elderly, weak and immunode-
pressed patients. For this reason, the increase in antibiotic
resistance of human pathogens [1,2] affects not only the treatment
of infectious diseases, but also many other medical practices, such
as immunosuppression in transplants, anticancer chemotherapy,
and advanced surgery. As stated by the World Health Organiza-
tion, the spread of antibiotic-resistant bacteria at hospitals
‘‘…means that commonplace medical procedures once previously
taken for granted could be conceivably consigned to medical
limbo. The repercussions are almost unimaginable’’ [3]. From this
perspective, studies addressing possible means to minimize and
eventually predict antibiotic resistance [4] must be considered a
priority for the future health of humankind.
To understand and predict the future evolution of antibiotic
resistance in bacterial pathogens, two different problems need to
be addressed: acquisition [5] of resistance genes (or mutations [6])
by formerly susceptible bacteria, and intrinsic antibiotic resistance.
The existence of previously unknown determinants of antibiotic
resistance that could be transferred to human pathogens and
might eventually constitute a health problem was addressed in a
recent report [7] in which it was shown that microbial antibiotic
producers in the environment have developed a large and versatile
arsenal of antibiotic resistance genes (resistome [8]).
In the current study, we focused on the second problem, the
existence of species-specific bacterial intrinsic resistome, defined as
the ensemble of chromosomal genes that are involved in intrinsic
resistance and whose presence in strains of a bacterial species is
independent of previous antibiotic exposure and is not due
horizontal gene transfer (HGT). Noteworthy, the most prominent
intrinsically-resistant bacteria have an environmental (non-clinical)
origin, in habitats that are much less likely than clinical settings to
present intense antibiotic selective pressure. This suggests [9] that the
main physiological role of the elements involved in this phenotype in
the natural habitats of these bacteria in not conferring resistance to
antibiotics currently in use in clinical practice. The intrinsic
resistome is thus an evolutionarily ancient phenotype common to
all strains of a bacterial species that has not been acquired as a result
of recent utilization of antibiotics for therapy.
To address the elements involved in the building-up of bacterial
intrinsic resistance, we investigated the intrinsic resistome of the
model organism Pseudomonas aeruginosa. [10,11,12,13]. This bacte-
rial species is the most important gram-negative nosocomial
pathogen with an environmental origin [13]. P. aeruginosa produces
infections, not only at hospitals [14], but associated to other basal
pathologies such as cystic fibrosis or HIV [10,15,16]. Besides its
virulence, one important feature of P. aeruginosa consists on its
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characteristic low susceptibility to antibiotics [17,18,19]. It is
worth to state that P. aeruginosa is a free-living organisms capable to
thrive in different environments [20]. Furthermore, it has been
shown that this bacterial species utilizes the same virulence
determinants to infect different hosts from plants to humans
[21,22,23,24,25], and that infective and environmental strains are
equivalent at the genomic [26,27] and physiological levels [28]. All
these indicate that several phenotypes relevant for P. aeruginosa
infection, including its characteristic low susceptibility to antibi-
otics, have been selected in natural environments distant from
human contact.
Intrinsic resistance to antibiotics is thought to result from the
reduced permeability of the bacterial envelope and the activity of
multidrug efflux pumps [29]. However, this lacks experimental
proof because an exhaustive search of other types of genes
involved in intrinsic resistance has not been performed. Establish-
ment of the genetic networks involved in the antibiotic resistance
of bacterial pathogens is thus of paramount relevance to
minimizing and predicting resistance, a task that has been recently
theoretically addressed [4]. In the present work, and using this
theoretical framework, a high-throughput analysis of the elements
involved in the intrinsic resistance of a bacterial pathogen is made.
The obtained data are important for predicting and fighting
resistance and for understanding the functional and ecological role
of antibiotic resistance determinants in natural ecosystems.
Results and Discussion
Two different transposon-tagged insertion libraries of P.
aeruginosa [30,31] were screened (Fig. 1) as described in Methods
to identify mutants with altered susceptibility to the following 6
antimicrobial agents belonging to different structural families:
polymixin B (polymixins), amikacin (aminocyclitols), ciprofloxacin
(fluoroquinolones), tetracycline (tetracyclines), imipenem (carba-
penems) and ceftazidime (cephalosporins). Altered susceptibility to
one or more antibiotics was observed in 222 of the 5952 tested
mutants (3.7%, Fig. 2). The position of the transposon was
determined by inverse-polymerase chain reaction [31], sequencing
of the amplicons, and comparison to the available sequence of P.
aeruginosa (http://www.pseudomonas.com/). After filtering inser-
tions occurring in the same gene, we have detected 112 loci in the
genome of P. aeruginosa that contribute to its characteristic
phenotype of antibiotic susceptibility (Supporting Online Material,
Table S1). Ninety nine of the insertions were located in open
reading frames already sequenced in the wild-type strain P.
aeruginosa PAO1, 8 were located in intergenic regions and 5 were
strain specific. Since the genome of P. aeruginosa contains 5570
genes, our results indicate that at least 1.8% of the genome of this
intrinsically resistant opportunistic pathogen contributes to its
characteristic phenotype of susceptibility to antibiotics. Among
these 112 loci, only one (a component of a multidrug efflux pump
mexD) has been previously annotated as an antibiotic resistance
gene. Although a few others, such as the putative RND efflux
transporters PA1436 or PA2527 are predicted to play a role in P.
aeruginosa resistance, the large majority of genes emerging form our
screen were not previously thought to play any role in the
antibiotic susceptibility of this bacterial species. Thus, our work
unveils a hidden intrinsic resistome in P. aeruginosa.
The combinations of classical antibiotics with drugs that
increase bacterial susceptibility, like for example beta-lactams/
beta-lactamases inhibitors [32], constitute a valuable therapeutic
tool. In the present work, we have identified genes (Supporting
Online Material, Table S1) which inactivation increases P.
aeruginosa susceptibility to several antimicrobials. Those genes
define novel targets for the development of anti-resistance drugs
such those above described.
Noteworthy, most mutants had altered susceptibility to multiple
antibiotics, indicating that the development of resistance is not
specific to a given antibiotic. The view that intrinsic resistance has a
large degree of non-specificity is also supported by the fact that many
of the products encoded by these genes are involved in basic
functions of the physiology of P. aeruginosa (Table 1). This absence of
specificity challenges the idea that each antibiotic resistance gene
originates as a means to avoid the activity of a particular antibiotic
[33]. Together with the notion that antibiotics do not only function
as weapons against competitors in Nature, but also as signal
molecules [34,35], our results demonstrate that antibiotic resistance
genes are more than shields, offering a more comprehensive view of
their physiological role in bacterial pathogens.
Most mutants exhibited enhanced resistance to antibiotics
(Fig. 2B) and 18% of them were resistant to all tested antibiotics.
The proteins involved include known and hypothetical outer
membrane proteins and transporters such as OmpA, CzcC,
PA0809, PA2760 and PA4691. These proteins likely serve to
transport the antibiotics inside the cell and thus might represent
mechanisms of resistance due to drug impermeability.
However, other mutations reducing susceptibility to all tested
antibiotics targeted genes encoding proteins involved in basic
cellular metabolism such as rafDI, which encodes for ADP-L-
glycero-D-mannoheptose-6-epimerase, and gapA, which encodes
glyceraldehyde 3-phosphate dehydrogenase. Slow-growing bacte-
ria are usually less susceptible to antibiotics [36]. Since strong
impairment of growth in rich medium was not observed for any
mutant, growth-independent features of the bacterial metabolome
must be responsible for the observed changes in antimicrobial
Figure 1. Screening of P. aeruginosa mutants with altered
antibiotic susceptibility. Two libraries of transposon-tagged P.
aeruginosa mutants were screened to detect changes in their
susceptibility to the antimicrobial agents polymixin B, amikacin,
ciprofloxacin, tetracycline, imipenem, and ceftazidime. A mutant was
considered resistant (red square in A) if it was able to grow at antibiotic
concentrations that inhibited the growth of the wild-type strain (black
square in both panels). A mutant was considered hypersusceptible
(green square in B) if it was not able to grow at antibiotic
concentrations permissive for the wild-type strain.
doi:10.1371/journal.pone.0001619.g001
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susceptibility. This highlights the fact that antibiotic susceptibility
is likely dependent on the metabolic state of bacteria [37,38]. That
is, in addition to the well-known specific mechanisms of resistance,
bacteria have a ‘‘physiology-dependent’’ resistome. During infection,
bacteria sense their environment and alter their metabolism
accordingly. Thus, knowledge on the changes that occur in bacterial
metabolic networks during infection may help us to improve
treatments, mainly at locations in the human-body where the
amount of free antibiotic is not very high. The fact that mutations
both in intergenic regions and mutations in regulatory proteins and
sensor systems affected bacterial susceptibility to antibiotics (see
Table 1) also supports the concept that in vivo susceptibility [39]
might be dependent on the tuning of physiological circuits in
response to the inputs received during infection.
Antibiotics have been sought and customized in order to
combat bacterial pathogens, and it was thought that their
ecological function is to fight competitors in natural (non-clinical)
environments. According to this warfare-based view, resistant
organisms should develop specific shields (antibiotic resistance
genes) to avoid the action of antibiotics. The acquisition of
antibiotic resistance genes by HGT supports this view, since such
genes use to be specific to a given structural family of antibiotics
and, in a few cases, the same gene is present in the producer
organism and in the bacterial pathogen [40]. Nevertheless, we
must remember that after HGT, classical antibiotic resistance
genes are displaced from the genetic background in which they
evolved and their function in the original organism is not
necessarily antibiotic resistance. Examples are P. aeruginosa strains
that were isolated from non clinical environments before the
discovery of quinolones but that have active mechanisms of
resistance to these synthetic drugs [28], and some antibiotic-
inactivating enzymes, prototypes of canonical antibiotic resistance
genes, that exert functions unrelated to antibiotics and important
to bacterial physiology [41,42]. These mechanisms of resistance
were not selected in the original organism to avoid the action of an
antibiotic, although they can provide this advantage upon transfer
to a new host, in what has been named an exaptation evolutionary
process [43]. As stated above, our results provide novel evidences
supporting the notion that some determinants involved in basic
bacterial physiology in natural habitats may have an important
role in resistance to environments with a high load of antibiotics,
such as hospital settings.
Figure 2. Antibiotic susceptibility of P. aeruginosa mutants. The susceptibility of the selected mutants was determined by comparison to the
wild-type parental strains. (A) The antibiotic susceptibility ratios of each mutant and its isogenic wild-type strain are shown. The ratios of changes
were hierarchically clustered [48] using freely available software (http://rana.lbl.gov/EisenSoftware.htm). Green, more susceptible; red, more resistant;
Pol, polymixin B; Amk, amikacin; Cip, ciprofloxacin; Tet, tetracycline; Imi, imipenem; Cef, ceftazidime. Note that in most cases, susceptibilities to
several antibiotics changed simultaneously. (B) The number of mutants with higher resistance (resistant mutants) to a given number of tested
antibiotics. Most of the mutants had increased resistance to several antibiotics belonging to different structural families. (C) The number of mutants
with higher susceptibility (hypersusceptible mutants) to a given number of tested antibiotics. Note that a mutant can be more resistant to some
antibiotics (see A) and more susceptible to others and therefore can be included in both (B) and (C).
doi:10.1371/journal.pone.0001619.g002
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Along our work, we found that the development of an intrinsic
resistance phenotype in P. aeruginosa requires the concerted action
of several genes that encode basic functions of cell physiology. Our
results support the notion that intrinsic resistance, and the capacity
to acquire higher levels of resistance may be the consequence of
complex networks of interactions among several bacterial proteins;
this opens a new field of research with regard to predicting
antibiotic resistance [4] in bacterial populations.
Several of the selected mutants are more resistant to antibiotics
than is the wild-type strain, such that mutations in these genes
might eventually play a role in acquired resistance during
treatment. The mechanisms of mutation-driven resistance are
usually purposefully sought using genes for which a role in
antibiotic resistance has already been described. Conversely, as yet
unknown antibiotic resistance genes, such as those described here,
have been ignored when examining the molecular basis of
mutation-driven resistance in P. aeruginosa.
In conclusion, intrinsic resistance to antibiotics and the ability to
evolve to higher levels of resistance involve a complex network of
elements, including non-classical antibiotic-resistance genes. Char-
acterization of the genes forming these networks will contribute to
accurate prediction of the emergence and evolution of antibiotic
resistance [4] and help to define new targets (hypersusceptible
mutants) for identifying antimicrobials against intrinsically resis-
tant bacterial pathogens.
Our work supports the notion that antibiotic resistance elements
are not just shields that evolved as protection mechanisms against
antibiotic weapons, but have several other functions relevant for
bacterial physiology. This is a Copernican turning point in our
view concerning antibiotic resistance and the functional and
ecological role of these elements in hospitals and in non-clinical
environments.
Materials and Methods
Bacterial strains and growth conditions
Two libraries of transposon-tagged P. aeruginosa mutants were
used. One of the libraries comprised 3936 mutants and has been
obtained from the P. aeruginosa Tb isolate [30]. The other
contained 2016 mutants and has been obtained from the P.
aeruginosa 59.20 strain [31]. For all experiments concerning
antibiotic susceptibility, bacteria were grown at 37uC in Mueller-
Hinton medium [44]. For obtaining chromosomal DNA, bacteria
were grown overnight at 37uC in LB broth without glucose [45] in
a rotary shaker operated at 220 rpm.
Screening of the libraries and determination of Minimal
Inhibitory Concentrations (MICs)
The screening was performed using Mueller-Hinton [44] agar
plates containing increasing concentrations (2-fold each plate) of
the following antimicrobial agents: polymixin B, amikacin,
ciprofloxacin, tetracycline, imipenem, ceftazidime. In all cases,
5 ml drops, each one containing around 104 colony-forming-units
of each mutant, were poured onto the plates, and the growth of the
spots was recorded after 24 h of growth. For comparison purposes,
all plates contained a spot with the corresponding wild-type strain.
In all cases, the tests were replicated at least three times. A mutant
was considered resistant if was capable to grow at antibiotic
concentrations that inhibited the growth of its parental, wild-type
strain. A mutant was classified as hypersusceptible to a given
antibiotic if did not grow at concentrations in which its parental
wild-type strain was capable to grow.
For all selected mutants, MICs to the six antibiotics were
determined in Mueller-Hinton [44] agar plates as described [46].
Determination of the point of insertion of the transposon
and identification of the mutated gene
Chromosomal DNA was obtained from the selected mutants
using the GENOME DNA KIT (MP Biomedicals). For each
mutant, 1 mg of genomic DNA was cut using 20 units of the
restriction enzyme PstI (Biolabs Inc.). The reaction was performed
at 37uC overnight. After inactivation of the restriction enzyme at
80uC for 20 minutes, 100 ng of the digested DNA was ligated with
200 units of T4 DNA ligase at 16uC overnight in 200 ml of ligation
Table 1. Functional categories of genes involved in the
antibiotic susceptibility of P. aeruginosa
Category*
Number of
genes in the
genome of
P. aeruginosa
PAO1**
Mutants with
changes in
antibiotic
susceptibility
belonging to
this functional
category**
Adaptation, protection 170 2 (1.2%)
Amino acid biosynthesis and metabolism 226 4 (1.8%)
Antibiotic resistance and susceptibility 31 1 (3.3%)
Motility and Attachment 112 4 (3.6%)
Biosynthesis of cofactors, prosthetic
groups and carriers
159 2 (1.3%)
Carbon compound catabolism 173 7 (4.05%)
Cell division 29 0 (-)
Cell wall/LPS/capsule 136 1 (0.7%)
Central intermediary metabolism 99 2 (2.0%)
Chaperons and heat shock proteins 54 0 (-)
Chemotaxis 64 1 (1.6%)
DNA replication, recombination,
modification and repair
88 1 (1.1%)
Energy metabolism 207 3 (1.4%)
Fatty acid and phospholipid metabolism 62 1 (1.6%)
Hypothetical, unclassified, unknown 2364 31 (1.3%)
Membrane proteins 676 17 (2.5%)
Nucleotide biosynthesis and metabolism 81 1 (1.2%)
Protein secretion/export apparatus 99 2 (2.02%)
Putative enzymes 477 11 (2.3%)
Related to phages, transposons, or
plasmids
65 2 (3.1%)
Transcription, RNA processing and
degradation: genes
55 0 (-)
Transcriptional regulators 473 5 (0.08)
Translation, post-translational
modification, degradation
195 1 (0.5%)
Transport of small molecules 595 17 (2.9%)
Two-component regulatory systems 121 4 (3.3%)
Secreted Factors (toxins, enzymes,
alginate): genes
88 1 (1.1%)
Non-coding RNA gene 97 0 (-)
Intergenic region - 8 (-)
Genes from non-PAO1 strain - 5 (-)
*Functional categories as defined in http://www.pseudomonas.com/
**Some genes belong to more than one category.
doi:10.1371/journal.pone.0001619.t001
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buffer (50 mM Tris-HCl, 10 mM MgCl2, 10 mM DTT, 1 mM
ATP, 25 mg/ml BSA, pH 7,5). These conditions favor autoligation
and circularization of the fragments. After ligation, DNA was
precipitated by adding 20 ml of 3 M sodium acetate, pH 5.2 and
500 ml of ethanol 100%. The mixture was incubated one hour at –
20uC, and the DNA was pelleted by centrifugation. Pelleted DNA
was washed with ethanol 70% and, after further centrifugation,
dried at 37uC. This dried DNA was used for inverse-PCR of the
circularized fragments generated from the chromosomal DNA
obtained from each mutant.
Inverse-PCR was made using the primers described in Table 2.
Primers Gm1 and phoA5 were used to map the location of the
transposon miniTnphoA3 in mutants belonging to the library
made in the strain 59.20 and primers Tn5c and Tn5d were used to
map the location of the transposon miniTn5 in the mutants
belonging to the library made in the strain TB. In all cases, the
PCR reaction was made in 50 ml reaction mixture containing 5 ml
of PCR buffer 10X (27.5 mM MgCl2, 20 mM Tris-HCl, 100 mM
KCl, 1 mM DTT, 0.1 mM EDTA, 0.5% Nonidet P40 v/v, 0.5%
Tween v/v, 50% glycerol v/v) each deoxynucleotide (dCTP,
dGTP. dATP and dTTP) at a concentration of 350 mM each,
300 nM of each primer, 2.5 units of Expand Long Template
Enzyme mix (Roche) and the template DNA obtained as described
above. The mixture was heated at 94uC for 2 min, followed by 30
cycles of 10 s at 94uC, 30 s at 55uC and 6 min at 68uC, and finally
one 7 min extension step at 68uC before the end of the reaction.
PCR products were run on 1% agarose gels and stained with
ethidium bromide [47]. For some mutants an amplicon was not
obtained using these experimental conditions. In these cases, the
experiment was repeated using the each one of the restriction
enzymes BstEII, NarI, SfoI, BamHI instead of PstI for the first
DNA digestion step. Before sequencing, the amplicons were
purified using QIAquick PCR purification protocol (Quiagen).
After purification, the amplicons were sequenced by the dideoxi
termination method with the same primers used for the PCR
reaction. The obtained sequences were used to make a Blast
search of the P. aeruginosa PAO1 genome (www.pseudomonas.com)
in order to map the position of the inserted transposon. In some
few mutants, the sequences were not present in the chromosome of
P. aeruginosa PAO1, and a general Blast search was performed. For
every mutant, the two sequences obtained with both primers
matched in the same gene or intergenic region of the sequenced
chromosome. This assures the reliability of the method used for
mapping the insertions.
Supporting Information
Table S1 Relative susceptibility and chromosomal position of P.
aeruginosa mutations that alter the level of antibiotic susceptibility.
Found at: doi:10.1371/journal.pone.0001619.s001 (0.16 MB
DOC)
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